Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post-discharge assessed by Respiratory Intensity and Impact Questionnaire.
Falsey AR, Walsh EE, Osborne RH, Vandendijck Y, Ren X, Witek J, Kang D, Chan E, Scott J, Ispas G. Falsey AR, et al. Among authors: scott j. Influenza Other Respir Viruses. 2022 Jan;16(1):79-89. doi: 10.1111/irv.12903. Epub 2021 Sep 2. Influenza Other Respir Viruses. 2022. PMID: 34472708 Free PMC article.
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, Godofsky E, Herring RW, Poleynard G, Sheikh A, Tobias H, Kugelmas M, Kalmeijer R, Peeters M, Lenz O, Fevery B, De La Rosa G, Scott J, Sinha R, Witek J. Lawitz E, et al. Among authors: scott j. Hepatology. 2016 Aug;64(2):360-9. doi: 10.1002/hep.28422. Epub 2016 Feb 19. Hepatology. 2016. PMID: 26704148 Free PMC article. Clinical Trial.
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
Wei L, Han T, Yang D, Heo J, Shang J, Cheng J, Chen X, Xie Q, Kim JH, Kalmeijer R, Ouwerkerk-Mahadevan S, Hoeben E, Lenz O, Verbinnen T, Sinha R, Li M, Scott J, Peeters M, Witek J; TIGER team. Wei L, et al. Among authors: scott j. J Gastroenterol Hepatol. 2016 May;31(5):912-20. doi: 10.1111/jgh.13288. J Gastroenterol Hepatol. 2016. PMID: 26777137 Clinical Trial.
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.
Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S, Schiff E, Davis M, Ruane P, Younes Z, Kalmeijer R, Sinha R, Peeters M, Lenz O, Fevery B, De La Rosa G, Scott J, Witek J. Kwo P, et al. Among authors: scott j. Hepatology. 2016 Aug;64(2):370-80. doi: 10.1002/hep.28467. Epub 2016 Mar 22. Hepatology. 2016. PMID: 26799692 Free PMC article. Clinical Trial.
Psychometric Validation of the Hepatitis C Symptom and Impact Questionnaire (HCV-SIQv4) in a Diverse Sample of Adults with Chronic Hepatitis C Virus Infection Treated with an Interferon-free Simeprevir-containing Regimen.
Trigg A, Chan E, Kitchen H, Willgoss T, Ho KF, Pierson R, Scott J. Trigg A, et al. Among authors: scott j. J Health Econ Outcomes Res. 2019 Feb 18;6(2):1-19. doi: 10.36469/9675. eCollection 2019. J Health Econ Outcomes Res. 2019. PMID: 32685576 Free PMC article.
Measuring respiratory syncytial virus infection severity in hospitalized children using the Pediatric Respiratory Syncytial Virus Electronic Severity and Outcome Rating System (PRESORS).
Vandendijck Y, Scott J, Heerwegh D, Van Der Elst W, Witek J, Sinha R, Fennema H. Vandendijck Y, et al. Among authors: scott j. Influenza Other Respir Viruses. 2022 Nov;16(6):1091-1100. doi: 10.1111/irv.13028. Epub 2022 Aug 14. Influenza Other Respir Viruses. 2022. PMID: 35965419 Free PMC article.
Evaluation of symptoms in respiratory syncytial virus infection in adults: psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire™ symptom scores.
Osborne RH, Nelson LM, Fehnel S, Williams N, Bender RH, Ziemiecki R, Gymnopoulou E, De Paepe E, Vandendijck Y, Norcross L, Heijnen E, Ispas G, Comeaux C, Callendret B, Chan EKH, Scott JA. Osborne RH, et al. J Patient Rep Outcomes. 2023 Jun 1;7(1):51. doi: 10.1186/s41687-023-00593-9. J Patient Rep Outcomes. 2023. PMID: 37261682 Free PMC article.
Monitoring Severity of Respiratory Syncytial Virus (RSV) in Infants and Young Children Using the Pediatric RSV Electronic Severity and Outcome Rating System (PRESORS): Results of Initial Quantitative Validation.
de la Loge C, Fofana F, Williams P, Rusch S, Stevens M, Scott J. de la Loge C, et al. Among authors: scott j. Patient Relat Outcome Meas. 2021 Jul 23;12:247-265. doi: 10.2147/PROM.S298736. eCollection 2021. Patient Relat Outcome Meas. 2021. PMID: 34326675 Free PMC article.
A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection.
Nilsson AC, Pullman J, Napora P, Luz K, Gupta A, Draghi J, Guzman Romero AK, Aggarwal N, Petrova G, Ianus J, Vijgen L, Scott J, Sinha R, Rusch S, Huntjens D, Bertzos K, Stevens M; ROSE Study Group. Nilsson AC, et al. Among authors: scott j. Clin Microbiol Infect. 2023 Oct;29(10):1320-1327. doi: 10.1016/j.cmi.2023.07.004. Epub 2023 Jul 6. Clin Microbiol Infect. 2023. PMID: 37422079 Clinical Trial.
10,492 results
You have reached the last available page of results. Please see the User Guide for more information.